- Home
- PWM vs IXHL Comparison
PWM vs IXHL Comparison
Compare PWM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- IXHL
- Stock Information
- Founded
- PWM 2018
- IXHL 2001
- Country
- PWM Hong Kong
- IXHL Australia
- Employees
- PWM N/A
- IXHL N/A
- Industry
- PWM
- IXHL
- Sector
- PWM
- IXHL
- Exchange
- PWM Nasdaq
- IXHL Nasdaq
- Market Cap
- PWM 34.6M
- IXHL 39.2M
- IPO Year
- PWM 2023
- IXHL N/A
- Fundamental
- Price
- PWM $1.73
- IXHL $1.93
- Analyst Decision
- PWM
- IXHL
- Analyst Count
- PWM 0
- IXHL 0
- Target Price
- PWM N/A
- IXHL N/A
- AVG Volume (30 Days)
- PWM 1.1M
- IXHL 24.2K
- Earning Date
- PWM 01-24-2025
- IXHL 11-14-2024
- Dividend Yield
- PWM N/A
- IXHL N/A
- EPS Growth
- PWM N/A
- IXHL N/A
- EPS
- PWM N/A
- IXHL N/A
- Revenue
- PWM $348,528.00
- IXHL $86,000.00
- Revenue This Year
- PWM N/A
- IXHL $3,817.06
- Revenue Next Year
- PWM N/A
- IXHL $66.67
- P/E Ratio
- PWM N/A
- IXHL N/A
- Revenue Growth
- PWM N/A
- IXHL N/A
- 52 Week Low
- PWM $0.67
- IXHL $1.50
- 52 Week High
- PWM $2.40
- IXHL $8.47
- Technical
- Relative Strength Index (RSI)
- PWM 61.42
- IXHL 52.16
- Support Level
- PWM $1.37
- IXHL $1.71
- Resistance Level
- PWM $1.55
- IXHL $2.19
- Average True Range (ATR)
- PWM 0.24
- IXHL 0.16
- MACD
- PWM 0.02
- IXHL -0.00
- Stochastic Oscillator
- PWM 88.34
- IXHL 41.12
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.